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BaCKgRoUND aND aIMS: Intrahepatic cholangiocar-
cinoma (iCCA) with liver metastases is perceived to have a 
poor prognosis, but the American Joint Committee on Cancer 
(AJCC) classifies them as early stage in the absence of lymph 
nodes or extrahepatic spread.
appRoaCH aND ReSUltS: Patients with iCCA from the 
European Network for the Study of Cholangiocarcinoma (ENS- 
CCA) and Surveillance, Epidemiology, and End Results (SEER) 
registries with survival/staging (AJCC v.7) data were eligible. 
Modified staging was used (mAJCC v.7): group A: stages I- III 
(excluding T2bN0); group B: stage IVa (excluding T2bN1M0); 
group C: liver metastases (T2bN0/1); and group D: stage IVb 
(extrahepatic metastases). Survival analysis (Kaplan- Meier and 
Cox regression) was performed in an ENS- CCA training cohort 
(TC) and findings internally (ENS- CCA iVC) and externally 
(SEER) validated. The aim was to assess whether liver metastases 
(group C) had a shorter survival compared to other early stages 
(group A) to propose a modified version of AJCC v.8 (mAJCC 
v.8). A total of 574 and 4,171 patients from the ENS- CCA and 
SEER registries were included. Following the new classification, 
19.86% and 17.31% of patients from the ENS- CCA and SEER 
registries were reclassified into group C, respectively. In the 
ENS- CCA TC, multivariable Cox regression was adjusted for 
obesity (p = 0.026) and performance status (P  <  0.001); pa-
tients in group C (HR, 2.53; 95% CI, 1.18- 5.42; P  =  0.017) 
had a higher risk of death (vs. group A). Findings were vali-
dated in the ENS- CCA iVC (HR, 2.93; 95% CI, 2.04- 4.19; 
P  <  0.001) and in the SEER registry (HR, 1.88; 95% CI, 1.68- 
2.09; P  <  0.001).
CoNClUSIoNS: iCCA with liver metastases has a worse 
outcome than other early stages of iCCA. Given that AJCC 
v.8 does not take this into consideration, a modification of 
AJCC v.8 (mAJCC v.8), including “liver metastases: multiple 
liver lesions, with or without vascular invasion” as an “M1a 
stage,” is suggested. (Hepatology 2021;73:2311-2325).
Biliary tract cancer (BTC) includes gallbladder cancer (GBC), cholangiocarcinoma (CCA), and ampullary tumors (AMPs). CCAs are 
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subdivided according to location into intrahepatic 
(iCCA) and extrahepatic CCA (eCCA). iCCA rep-
resents the second- most common primary liver cancer 
after HCC.(1) iCCA has received substantial atten-
tion in recent years given the progressive worldwide 
increase in incidence. Prognosis is poor because of 
the fact that BTCs usually present in advanced stages 
attributable to their asymptomatic nature in early 
stages.(2,3) Thus, there is an urgent need to develop 
better diagnostic and therapeutic strategies for patients 
affected by these cancers.(4- 6)
For many years, iCCAs were joined together 
with other BTCs, and clinical trials have tradition-
ally recruited all subgroups of BTC. In fact, current 
standard- of- care adjuvant(7,8) and palliative(9- 12) che-
motherapy for BTC does not distinguish between 
BTC subtypes. In contrast, there is increasing evidence 
suggesting that iCCA, eCCA, GBC, and AMPs have 
different etiological, clinical, genomic, and molecular 
characteristics.(5)
Among all BTCs, iCCAs are gaining lots of atten-
tion for a variety of reasons. First, patients diagnosed 
with iCCA rarely present with biliary obstruction 
and jaundice, which may lead to an increased per-
centage of patients diagnosed with advanced disease, 
when no curative options are available.(6) In addi-
tion, chronic liver diseases (NAFLD, viral hepatitis 
[B or C], and cirrhosis) are well- known risk factors 
for both iCCA and HCC, making radiological dif-
ferentiation of iCCA from HCC in patients with 
underlying liver disease challenging. However, most 
iCCAs develop in the absence of underlying liver dis-
ease, thus making screening programs challenging.(6) 
Second, a proportion of iCCAs may develop multiple 
liver lesions (“liver metastases”), with no evidence of 
extrahepatic disease; therefore, liver- directed thera-
pies(13,14) and external beam radiotherapy(15) could 
be used as potential treatment options. Third, there 
is evidence suggesting that patients diagnosed with 
iCCA have a better prognosis compared to other 
advanced BTCs.(16) Finally, there is strong evidence 
indicating that genomic and molecular aberrations in 
iCCA differ from other BTCs,(17) mainly represented 
by increased presence of fibroblast growth factor 
receptor 2 fusion rearrangements and isocitrate dehy-
drogenase- 1 and - 2 mutations.(18,19) Identification of 
these molecular alterations has direct implications for 
access to targeted therapies and precision medicine 
strategies, whose success is currently almost limited 
to iCCA among the BTCs.(20)
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The most commonly used staging classification in 
oncology is the one developed by the American Joint 
Committee on Cancer (AJCC).(21) Staging criteria 
for CCA were not introduced until the 2nd Edition 
(published in 1983 and made effective in 1984).(22) 
In addition, iCCA was staged together with other 
primary liver tumors, such as HCC, and it was not 
until the 7th Edition (published in 2009 and effec-
tive between 2010 and 2017; AJCC v.7; Table 1)(23) 
that a specific staging system for iCCA was provided. 
The latest update was published in 2016 and made 
effective in 2018 (8th Edition).(23) Several changes 
were applied in this latest version, involving, in par-
ticular, the tumor (T) staging (AJCC v.8; Table 1). 
The T1 category was subdivided according to tumor 
size, whereas the T3 and T4 definitions were slightly 
modified and assigned to stage III disease (if M0). 
Moreover, the previously defined T2a (solitary lesion 
with vascular invasion) and T2b (multiple tumors; so- 
called liver metastases for the purpose of this study) 
categories were merged.
As stated above, a significant proportion of patients 
(up to 48%) with iCCA may develop multiple liver 
lesions in the absence of other extrahepatic metasta-
ses.(16) This liver- only pattern is not unique to iCCA, 
but can also be observed in other primary liver cancers, 
such as HCC. In HCC, the scenario of multiple liver 
lesions may represent multiple primary tumors (mul-
tifocal disease) arising in the background of cirrhosis. 
However, this phenomenon is still elusive in iCCA, 
especially when detected in the absence of a preexist-
ing liver disease such as cirrhosis, primary sclerosing 
cholangitis, or exposure to specific chemicals.(24- 26) In 
the majority of patients diagnosed with iCCA, pres-
ence of multiple liver lesions usually reflects hema-
togenous intrahepatic dissemination (liver metastases) 
from a primary predominant tumoral liver lesion and 
is clinically expected to feature worse prognosis, more 
similar to metastatic disease than to earlier stages. In 
fact, these patients are usually managed with palliative 
strategies, similar to conditions where other distant 
metastases have been identified.(27) In contrast, cur-
rent staging systems, such as the AJCC, do not take 
account for this issue and, in the absence of other sites 
of distant metastases, the AJCC still classifies liver 
metastases in iCCA as early stage in the absence of 
lymph node or extrahepatic spread(23,28) (Table 1).
The European Network for the Study of 
Cholangiocarcinoma (ENS- CCA) represents an 
open, multidisciplinary group of clinical, trans-
lational, and basic researchers aiming to improve 
the knowledge on CCA and promote translational 
activities; as part of the ENS- CCA initiatives, 
a multicenter pan- European clinical registry of 
patients with CCA has been in development since 
2016, including both retrospective (from 2010) and 
prospective data.(4) This study aimed to describe the 
outcomes of patients with iCCA complicated by 
liver metastases and compare them to other earlier 
stages, in order to ascertain whether current staging 
accurately reflects natural behavior and aggressive-
ness, or whether any changes to the current staging 
system should be considered.
Patients and Methods
StUDy DeSIgN
A modified version of the AJCC v.7 staging crite-
ria (mAJCC v.7; Table 1), where patients diagnosed 
with liver metastases (T2b) were classified as a sep-
arate group (group C) regardless of node (N) status 
(any N) and in the absence of other sites of dis-
tant metastases (M0), was generated. Groups were 
defined as follows: group A (stages I- III [exclud-
ing T2bN0M0]); group B (stage IVa [excluding 
T2bN1M0]); group C (liver metastases: multiple 
liver lesions, with or without vascular invasion [T2b, 
any N, M0], group of interest); and group D (stage 
IVb [M1 extrahepatic disease]).
The primary objective of this study was to apply 
both the AJCC v.7 and mAJCC v.7 classification to 
assess whether patients with liver metastases (regard-
less of lymph node status; group C) had a differ-
ent prognosis compared to other early- stage disease 
(stages I- III; group A), using overall survival (OS) as 
the primary end- point (defined as the time from first 
diagnosis to death/last visit). Given that the AJCC v.8 
classification does not differentiate between number 
of liver lesions (T2 stage includes solitary lesions with 
vascular invasion and multiple liver lesions within the 
same group), the analysis was performed using the 
AJCC v.7 (which provides the distinction between 
T2a and T2b subgroups).
The secondary objective was to create a modified 
AJCC v.8 (mAJCC v.8) that could be used for the 
development of future AJCC versions.
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taBle 1. Current Staging of CCa (aJCC 7th and 8th editions and Corresponding Modified Versions)
iCCA
AJCC v.7
mAJCC v.7 Modified version used to 
assess impact of liver metastases AJCC v.8
mAJCC v.8 Proposed modified 
version of the current AJCC v.8
Primary tumor (T)
TX Primary tumor cannot 
be assessed.
Primary tumor cannot be assessed. Primary tumor cannot be 
assessed.
Primary tumor cannot be 
assessed.
T0 No evidence of primary 
tumor
No evidence of primary tumor No evidence of primary tumor No evidence of primary tumor
Tis Carcinoma in situ (intra-
ductal tumor)
Carcinoma in situ (intraductal 
tumor)
Carcinoma in situ (intraductal 
tumor)
Carcinoma in situ (intraductal 
tumor)
T1 Solitary tumor without 
vascular invasion
Solitary tumor without vascular 
invasion
— — 
T1a — — Solitary tumor ≤5 cm without 
vascular invasion
Solitary tumor ≤5 cm without 
vascular invasion
T1b — — Solitary tumor >5 cm without 
vascular invasion
Solitary tumor >5 cm without 
vascular invasion
T2 — — Solitary tumor with intrahe-
patic vascular invasion or 
multiple tumors with or 
without vascular invasion
Solitary tumor with intrahepatic 
vascular invasion
T2a Solitary tumor with 
vascular invasion
Solitary tumor with vascular invasion — — 
T2b Multiple tumors, with 
or without vascular 
invasion
Multiple tumors, with or without 
vascular invasion
— — 
T3 Tumor perforating the 
visceral peritoneum 
or involving local 
hepatic structures by 
direct invasion
Tumor perforating the visceral peri-
toneum or involving local hepatic 
structures by direct invasion
Tumor perforating the visceral 
peritoneum
Solitary tumor perforating the 
visceral peritoneum
T4 Tumor with periductal 
invasion
Tumor with periductal invasion Tumor involving local extra-
hepatic structures by direct 
invasion
Solitary tumor involving local 




NX Regional lymph nodes 
cannot be assessed.
Regional lymph nodes cannot be 
assessed.
Regional lymph nodes cannot 
be assessed.
Regional lymph nodes cannot be 
assessed.
N0 No regional lymph node 
metastasis
No regional lymph node metastasis No regional lymph node 
metastasis
No regional lymph node 
metastasis
N1 Regional lymph node 
metastasis present
Regional lymph node metastasis 
present
Regional lymph node metas-
tasis present




M0 No distant metastasis No distant metastasis No distant metastasis No distant metastasis
M1 M1a: liver metastases: multiple 








0 Tis, N0, M0 Tis, N0, M0 Tis, N0, M0 Tis, N0, M0
I T1, N0, M0 T1, N0, M0 (group A) — T1, N0, M0
Ia — — T1a, N0, M0 T1a, N0, M0
Ib — — T1b, N0, M0 T1b, N0, M0
II T2a/b, N0, M0 T2a, N0, M0 (group A) T2, N0, M0 T2, N0, M0
 
Hepatology, Vol. 73, No. 6, 2021 LAMARCA ET AL.
2315
In order to generate the above- mentioned stag-
ing groups, individual patient data on the T, N, and 
metastasis (M) stage was individually reviewed and 
staging groups defined for individual patients. As a 
quality control, patients with mismatching informa-
tion were reviewed (if required) or excluded (if unable 
to satisfactorily reply to issued queries).
DeFINItIoN oF a MoDIFIeD 
StagINg SySteM: tRaININg 
aND INteRNal ValIDatIoN 
CoHoRtS
Data from patients included in the ENS- CCA 
registry up to February 2019 were retrospectively 
analyzed. In order for data to be included in the reg-
istry, individual sites involved had obtained appropri-
ate ethical approval; ethical guidelines of the 1975 
Declaration of Helsinki were met. Eligible patients 
were those with a diagnosis of iCCA with available 
data of survival and staging (according to AJCC 
v.7). Patients diagnosed with mixed HCC- iCCA or 
with different subtypes of CCA were excluded. Two 
cohorts of patients were analyzed: (1) the training 
cohort, including consecutive patients in the ENS- 
CCA registry from The Christie NHS Foundation 
Trust, who had been diagnosed between 2013 and 
2017; (2) the internal validation cohort, including 
consecutive patients in the ENS- CCA registry from 
The Christie NHS Foundation Trust, who had been 
diagnosed between 2017 and 2018, along with all 
patients included in the ENS- CCA registry by other 
contributing centers (2013- 2018). The aim was to 
use the training cohort for building a modified stag-
ing system and for these results to be validated in the 
internal validation cohort. By doing so, lessons learned 
from the training cohort could be used to improve the 
modified staging system before its application in the 
internal validation cohort, should this be required.
All eligible patients included in this study were 
staged as per AJCC v.7 and mAJCC v.7 classification. 
The following assumptions were made at time of data 
interpretation: if metastatic sites were not reported, M 
stage was assumed to be M0; when presence/absence of 
lymph node metastases were unknown (Nx), these were 
assumed to be N0 disease; if two separate T or N stages 
were reported, the highest stage was used for analysis 
purposes. Patients with M0 disease with reported T2 
tumors were excluded from the analysis if no further 
specification regarding T2a/T2b was provided.
Statistical analysis
The last update of clinical data was in February 
2019. Patients who were alive at the time of the last 
follow- up were censored. Survival analysis was first 
performed in the training cohort, and then findings 
were validated in the internal validation cohort. Chi- 
square, Fisher’s exact- test, and t test were used when-
ever appropriate. The Kaplan- Meier method was used 
to estimate median OS. Additional survival analy-
ses with univariate Cox regression and a log- rank 
test were also performed. Step- wise Cox regression, 
including all baseline characteristics collected as part 
of the ENS- CCA registry (including staging), was 
used for identification of variables of interest to be 
included in the multivariable Cox regression model 
(P value cutoff, 0.05). In order to adjust the multi-
variable Cox regression model to potential confound-
ing factors impacting on patients’ outcome for which 
relying on statistical significance in the step- wise Cox 
regression model alone would not be fully appropriate, 
iCCA
AJCC v.7
mAJCC v.7 Modified version used to 
assess impact of liver metastases AJCC v.8
mAJCC v.8 Proposed modified 
version of the current AJCC v.8
III T3, N0, M0 T3, N0, M0 (group A) — — 
IIIa — — T3, N0, M0 T3, N0, M0
IIIb — — T4, Any N, M0 or any T, N1, M0 T4, N0, M0 or any T, N1, M0
IV — Any T, any N, M1 — 
IVa T4, N0, M0 or any T, 
N1, M0
T4, N0, M0 or any T (except T2b), N1, 
M0 (group B)
— Any T, any N, M1a
— — T2b, any N, M0 (group C) — — 
IVb Any T, any N, M1 Any T, any N, M1 (group D) — Any T, any N, M1b
taBle 1. Continued
Hepatology, June 2021LAMARCA ET AL.
2316
a few variables with a well- defined prognostic impact 
were preselected to be included in the multivariable 
Cox regression model regardless of the step- wise Cox 
regression findings. These factors included: stage and 
performance status, in view of previous evidence sug-
gesting their impact on OS in this disease group.(16)
Two- sided P values of <0.05 were considered sta-
tistically significant. Stata software (version 12.0; 
StataCorp LP, College Station, TX) was used for the 
statistical analysis.
Sensitivity analysis
In order to confirm that our originally proposed 
definition of group C was adequate, a sensitivity anal-
ysis was performed. Given that the impact of lymph 
node positivity (N1) in the presence of liver metastases 
(T2b) is uncertain, a sensitivity analysis in the whole 
ENS- CCA series by limiting group C to patients with 
N0 disease only (patients with N1 disease would be 
classified as group B) was completed. In the sensitivity 
analysis, group B was defined as “stage IVa, includ-
ing T2b, N1, M0”) and group C as “T2b, N0, M0” 
(instead of “T2b, any N, M0” as defined for the rest 
of the analysis in this article). A decision was made to 
keep patients with N1 in group B instead of removing 
them from the analysis to explore whether prognosis 
was driven by liver metastases (T2b) on their own and 
independent from the presence of N1 disease.
eXteRNal ValIDatIoN: 
SURVeIllaNCe, epIDeMIology, 
aND eND ReSUltS RegIStRy
Data extracted from the Surveillance, Epidemiology, 
and End Results (SEER) registry were used for external 
validation.(29) Cases reported from 1975 through 2016 
with available data on survival and stage (as per AJCC 
v.7) were deemed eligible. The staging assumptions 
used for the ENS- CCA cohort were applied for the 
SEER registry. External validation with SEER data was 
aimed at confirming whether patients with liver metas-
tases (regardless of lymph node status; group C) had 
indeed a different outcome compared to other “early- 
stage” disease (stages I- III; group A). Survival analysis 
with SEER data was performed using Cox regression 
analysis (multivariable analysis performed with ENS- 
CCA data was planned to be reproduced, if variables of 
interest were available in the SEER dataset; otherwise, 
only a univariate analysis would be conducted).
DeFINItIoN oF tHe pRopoSeD 
UpDateD aJCC ClaSSIFICatIoN
Based on the information derived from mAJCC v.7 
and the outcome of the current staging group, changes 
to the current AJCC v.8 in the form of an mAJCC 
v.8 were proposed, and outcomes of each specifically 
defined group were assessed in the joined ENS- CCA 
and SEER cohort. Survival analysis was performed 
according to the previously indicated methodology.
Results
patIeNt CHaRaCteRIStICS:  
eNS- CCa RegIStRy
Of the 1,820 patients included in the ENS- CCA 
registry, 810 had been diagnosed with iCCA and were 
assessed for eligibility. A total of 574 patients were eli-
gible (141 within the training cohort [24.56%] and 433 
in the internal validation cohort [75.44%]). Figure 1A 
summarizes patient flow for the ENS- CCA cohort.
Patient baseline characteristics, including treatment, 
for both the training and internal validation cohorts, 
are summarized in Table 2. Median follow- up time 
was 11.01 months (range, 0.00- 183.12; interquartile 
range [IQR], 4.03- 23.89) for the whole cohort; 8.99 
(range, 0.00- 57.96; IQR, 3.48- 18.01) for the training 
cohort; and 11.39 (range, 0.00- 183.12; IQR, 4.31- 
25.93) for the internal validation cohort (P = 0.0017). 
For the whole cohort, median age at diagnosis was 
66.16 years (range, 26- 92); the majority of patients 
were Eastern Cooperative Oncology Group perfor-
mance status (ECOG- PS) 0 (41.99%) or 1 (35.89%). 
Obesity and diabetes were present in 20.21% and 
20.21% of patients, respectively. With respect to treat-
ments, 47.21% of patients underwent previous surgi-
cal resection (5.67% and 60.74% in the training and 
internal validation cohorts, respectively; P  <  0.001), 
whereas palliative chemotherapy was offered to 39.37% 
of patients (60.28% and 32.56% in the training and 
internal validation cohorts, respectively; P < 0.001).
StagINg oF iCCa: eNS- CCa 
RegIStRy
Staging groups in the ENS- CCA registry, accord-
ing to the AJCC v.7, mAJCC v.7, and mAJCC v.7 
adjusted for sensitivity analysis are shown in Table 3. 
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When the whole population was staged based on the 
AJCC v.7 classification, 46.52%, 22.3%, and 31.18% 
of patients were stages I- III, IVa, and IVb disease, 
respectively. When applying the mAJCC v.7 classi-
fication, a total of 114 of the 395 (28.9%) patients 
previously staged as I- IVa were reclassified into group 
C (75 N0; 39 N1), with 33.45%, 15.51%, 19.86%, and 
31.18% of patients staged within groups A, B, C, and 
D, respectively.
SURVIVal aNalySIS: eNS- CCa 
RegIStRy
Estimated median OS was 9.98 (95% CI, 6.96- 
11.99; 135 events; 95.74% of patients), 18.52 (95% 
CI, 15.44- 22.07; 280 events; 64.67% of patients), 
and 15.01 months (95% CI, 12.64- 16.95; 415 events; 
75.30% of patients) for the training, internal valida-
tion, and whole ENS- CCA cohorts, respectively.
In the training cohort, univariate survival analy-
sis confirmed that both staging systems (AJCCv.7 
and mAJCC v.7) had an impact on OS (Supporting 
Information S1A), with patients with distant metas-
tases (stage IVb) demonstrating shorter OS. Similar 
findings were obtained in the univariate analysis 
using the internal validation cohort (Supporting 
Information S1B).
Step- wise multivariable Cox regression analy-
sis performed in the training cohort (Supporting 
Information S2) identified stage (HR, 1.37; 95% CI, 
1.10- 1.69; P  =  0.004), obesity (HR, 0.56; 95% CI, 
0.34- 0.91- 1.69; P  =  0.018), and ECOG- PS (HR, 
1.89; 95% CI, 1.51- 2.39; P  <  0.001) as prognostic 
variables of interest to be included in the multivari-
able analysis. Presence of background liver cirrhosis 
did not impact on OS (P = 0.917). The multivariable 
Cox regression model, adjusted for these variables in 
the training cohort, confirmed that patients classified 
FIg. 1. Patient flow. N refers to number of patients. (A) Patient flow for patients included in the ENS- CCA registry. (B) Patient flow 
for patients included in the SEER registry.
A
Patients included in the
ENS-CCA registry
N=1,820
Patients diagnosed with iCCA
N=810
Eligible patients (ENS-CCA cohort)
N=554
Training set (N=141)
Internal validation set (N=433
Excluded (N=1,010)
•  Hilar cholangiocarcinoma (N=609)
•  Distal cholangiocarcinoma (N=309)
•  Mixed HCC-CCA (N=32)
•  Not specified (N=60)
Excluded (N=256)
•  No survival/staging data available (N=256)
B
Patients included in the SEER
registry
Patients diagnosed with iCCA
N=15,601
Eligible patients (SEER cohort)
N=4,171
External validation set (N=4,171)
Excluded (N=11,430)
•  No staging data available (N=11,421)
•  No survival data available (N=9)
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in group C (liver metastases) as per the mAJCC v.7 
had a worse outcome than patients with early stage 
(group C [vs. group A] HR, 2.53; 95% CI, 1.18- 
5.42; P  =  0.017). These findings were validated in 
the internal validation cohort (group C [vs. group A] 
HR, 2.93; 95% CI, 2.04- 4.19; P < 0.001; Supporting 
Information S3).
SeNSItIVIty aNalySIS: eNS- CCa 
RegIStRy
For the sensitivity analysis, only the 75 patients 
with pT2bN0 were included in group C (Table 3), 
whereas patients with T2bN1 disease were classi-
fied as group B (128 patients). When taking this 
approach, multivariable Cox regression analysis 
applied to the whole series confirmed that liver 
metastases had a prognostic effect, which was inde-
pendent from lymph node status (group C [vs. 
group A] HR, 2.51; 95% CI, 1.76- 3.56; P  < 0.001; 
Supporting Information S4). When the outcome of 
patients with T2bM0 disease were analyzed accord-
ing to N status (total of 114 patients; 75 T2bN0 
and 39 T2bN1), N1 disease was shown to be asso-
ciated with worse OS (median OS for patients with 
T2bN0 was 11.82 months [95% CI, 7.89- 20.19], 
median OS for patients with T2bN1 was 8.99 
months [95% CI, 5.02- 14.61]; T2bN1 [vs. T2bN0] 
HR, 1.68; 95% CI, 1.10- 2.57; P = 0.015). These two 
observations supported our analysis to continue with 
the originally proposed definition of group C (T2b, 
any N, M0).
taBle 2. patient Baseline Characteristics and Summary of treatments Received (eNS- CCa Registry)
Patient Characteristics









Validation)N % N % N %
Sex Female 279 48.61 88 62.41 191 44.11 <0.001
Male 295 51.39 53 37.59 242 55.89
Age (years) Median (range) 66.16 (26- 92) 65.83 (28- 90) 66.15 (26- 92) 0.4462
Ethnicity Caucasian 539 93.90 122 86.52 417 96.30 <0.001
Other 20 3.49 7 4.97 13 3.01
Not reported 15 2.61 12 8.51 3 0.69
Obesity Yes 116 20.21 28 19.86 88 20.32 0.693
Diabetes mellitus Yes 116 20.21 27 19.15 89 20.55 0.709
Liver cirrhosis Yes 53 9.23 3 2.13 50 11.55 <0.001
Primary sclerosing 
cholangitis
Yes 10 1.74 0 0.00 10 2.31 0.130
ECOG- PS 0 241 41.99 22 15.60 219 50.58 <0.001
1 206 35.89 58 41.13 148 34.18
2 78 13.59 35 24.82 43 9.93
3 43 7.49 24 17.02 19 4.39
4 5 0.87 2 1.42 3 0.69
Not reported 1 0.17 0 0 1 0.23
Patient treatment N % N % N %
Previous surgery Yes 271 47.21 8 5.67 263 60.74 <0.001
Adjuvant 
treatment*
Yes 49 8.54 1 0.71 48 11.09 0.314
Tumor recurrence Yes 113 19.69 7 4.96 106 24.48 <0.001
Clinical trials Yes 37 6.45 21 14.89 16 3.70 <0.001
Palliative 
chemotherapy
Yes 226 39.37 85 60.28 141 32.56 <0.001
N refers to number, % to percentage.
*Adjuvant treatment was not standard of care at the time these patients were treated. Chi- square, Fisher’s exact test, and t test P values are 
provided (as appropriate).
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eXteRNal ValIDatIoN: SeeR 
RegIStRy
Among 15,601 records provided by the SEER 
database, 4,171 were deemed eligible (Fig. 1B); their 
baseline and staging characteristics are summarized in 
Supporting Information S5. All eligible patients were 
diagnosed between 2010 and 2015. Median follow- up 
was 8 months (range, 0- 83; IQR, 2- 18). Median OS 
was 10 months (95% CI, 9- 10; 3,434 events; 82.33% 
of patients), with 17.31% of patients classified in 
group C (liver metastases).
Univariate survival analysis confirmed that patients 
classified in group C (liver metastases) as per the 
mAJCC v.7 had a poorer outcome than patients with 
early stage (group C [vs. group A] HR, 1.88; 95% CI, 
1.68- 2.09; P  < 0.001; Supporting Information S1D). 
Since obesity and ECOG- PS data was not available, 
multivariable analysis could not be performed.
oUtCoMeS FoR eaCH Stage 
gRoUp
Figure 2 summarizes patients’ outcome for each 
disease stage, following both the standard AJCC v.7 
(Fig. 2A) and the mAJCC v.7 (Fig. 2B) for ENS- 
CCA (whole population). Outcomes of mAJCC 
v.7 in the SEER cohort are also shown (Fig. 2C). 
The updated mAJCC v.7 classification in the ENS- 
CCA cohort (Fig. 2B) and SEER registry (Fig. 2C) 
showed that compared to stage I disease, risk of 
death steadily increased through stage progression 
(stage I  >  stage II [excluding T2bN0M0]  >  stage 
III > stage IVa [excluding T2bN1M0] >  liver metas-
tases [T2bN0/1M0] > stage IVb).
Data from the ENS- CCA registry (Fig. 2B) showed 
that when group C was used as the reference group, 
patients diagnosed with early- stage disease group A 
(stages I- III) had a lower risk of death than group 
C (stage I [vs. liver metastases]; HR, 0.28; 95% CI, 
0.19- 0.40; P  <  0.001; stage II [vs. liver metastases]; 
HR, 0.48; 95% CI, 0.28- 0.81; P = 0.007). Compared 
to group C, groups B and D showed a trend toward 
longer and shorter survival, respectively, but differ-
ences did not reach statistical significance (P = 0.118 
and P = 0.247, respectively).
Survival analysis confirmed similar trends in the 
SEER registry (Fig. 2C). Patients diagnosed with 
stage I and stage II had a lower risk of death com-
pared to group C. Differences between group A/
stage III and group C (reference category) did not 
reach statistical significance (P  =  0.302). Similar to 
what had been identified in the ENS- CCA cohort, 
group B (P = 0.016) and group D (P < 0.001) showed 
longer and shorter survival compared to group C, 
respectively.
taBle 3. Staging of patients: aJCC v.7 and proposed maJCC Classification (eNS- CCa Registry)
Staging of Patients




Internal Validation Cohort 
(N = 433)
N % N % N %
AJCCv.7 Stages I- III (including T2bN0M0; liver 
satellite lesions)
267 46.52 43 30.50 224 51.73
Stage IVa (including T2bN1M0) 128 22.30 28 19.86 100 23.09
Stage IVb (distant mts) 179 31.18 70 49.65 109 25.17
mAJCC Group A: stages I- III (excluding T2bN0M0) 192 33.45 13 9.22 179 41.34
Group B: stage IVa (excluding T2bN1M0) 89 15.51 20 14.18 69 15.94
Group C: stage T2bN0/1M0: liver mts 114 19.86 38 26.95 76 17.55
N0 75 30 45
N1 39 8 31
Group D: stage IVb 179 31.18 70 49.65 109 25.17
mAJCC (sensitivity 
analysis)
Group A: stages I- III (excluding T2bN0M0) 192 33.45 13 9.22 179 41.34
Group B: stage IVa (including T2bN1M0) 128 22.30 28 19.86 100 23.09
Group C: stage T2bN0M0: liver mts 75 22.30 30 21.28 45 10.39
Group D: stage IVb 179 31.18 70 49.65 109 25.17
N refers to number, % to percentage.
Abbreviation: mts, metastases.
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pRopoSeD CHaNgeS to tHe 
CURReNt StagINg SySteM: 
maJCC v.8
Based on these findings, we proposed some changes 
to the current AJCC v.8 (mAJCC v.8; Table 1). Stage 
IV were divided into two groups: stage IVa (M1a dis-
ease; liver metastases regardless of N status) and stage 
IVb (M1b disease; extrahepatic metastases, regardless 
of T and N status). The updated M1a included liver 
metastases (defined as the presence of multiple liver 
lesions, with or without vascular invasion). In this 
respect, stage II was restricted to patients with soli-
tary tumors with vascular invasion and in the absence 
of lymph node or other distant metastatic localiza-
tions (T2N0M0). Stage III encompassed T3N0M0, 
T4N0M0, and AnyTN1M0 patients according to the 
latest AJCC v8 classification; our findings from the 
mAJCC v.7 supported this approach given that these 
subpopulations shared a similar prognosis (Fig. 2B,C).
When these criteria were applied to the whole 
cohort of joined ENS- CCA and SEER patients, dif-
ferences between all these staging groups reached sta-
tistical significance, when compared with either stage 
I or stage IVa as the reference category (Fig. 3B). 
Multivariable survival analysis was not performed 
given the lack of data from the SEER registry (no data 
on ECOG- PS available for the SEER registry). In 
order to allow comparison with the preceding staging 
system (AJCC v.7), Fig. 3A provides survival outcome 
using this classification in the whole cohort of joined 
ENS- CCA and SEER patients. Harrell’s C index was 
slightly higher for the mAJCC v.8 (Fig. 3B; C index, 
0.624) than for the AJCC v.7 (Fig. 3A; C index, 0.614).
Discussion
Staging classifications are in constant evolution 
and require frequent review.(30,31) The present study 
confirms that the presence of liver metastases is a 
feature of poor prognosis in patients with iCCA 
independent of lymph node status. Based on these 
findings, future staging classifications should be 
adjusted to classify iCCA patients with liver metas-
tases as a separate group (M1a), regardless of N 
status and in the absence of other sites of distant 
metastases (mAJCC v.8; Table 1). Our proposed 
modification of the current AJCC v.8 confirms that 
patients in this group have a worse prognosis com-
pared to stage I- III disease and a better prognosis 
compared to patients with extrahepatic metastases 
(M1b). This was also suggested back in 2009 by 
Nathan et al., who showed that patients with liver 
metastases from iCCA had an increased risk of 
death (HR, 1.42; 95% CI, 1.01- 2.10; P < 0.005).(32) 
Other studies have also shown similar findings, with 
liver metastases exerting a negative impact on prog-
nosis.(33) For his reason, presence of liver metastasis 
in iCCA is regarded, by many, as a contraindication 
to surgery.(34) Moreover, identifying the subset of 
iCCAs with liver metastases also has translational 
relevance. This finding is consistent with a defin-
ing biological feature of the tumor, that is, the early 
intrahepatic dissemination promoted by perineural 
invasion, portal encasement, and intraductal growth 
that frequently occurs before lymph node and hema-
togenous spread.(35)
These changes in staging classifications may affect 
a significant number of patients given that ~20% of 
patients diagnosed with iCCA fall into this group. 
The implementation of the proposed reclassifica-
tion is likely to have clinical implications at the time 
of treatment decision, allowing for a clearer patient 
selection given that patients with M1a disease would 
be suitable for strategies for advanced disease, includ-
ing liver- directed therapies and locoregional strat-
egies.(16) Based on our results, patients with liver 
metastases should not be offered therapeutic strate-
gies suitable for early stages, in view of poor survival. 
FIg. 2. OS for each stage groups. (A) Kaplan- Meier for the ENS- CCA cohort using AJCC v.7 is shown; multivariable Cox regression 
HRs are shown for the stage variable (with stage I as the reference category); the multivariable HR for obesity was 0.79 (95% CI, 0.62- 
1.03; P = 0.083), and the multivariable HR for ECOG- PS (continuous variable) was 1.69 (95% CI, 1.51- 1.89; P < 0.001). (B) Kaplan- 
Meier for the ENS- CCA cohort using mAJCC v.7 is shown; multivariable Cox regression HRs are shown for the stage variable (separately 
for analysis with stage I and group C as reference categories); the multivariable HR for obesity was 0.81 (95% CI, 0.63- 1.05; P = 0.113), 
and the multivariable HR for ECOG- PS (continuous variable) was 1.68 (95% CI, 1.49- 1.89; P < 0.001). (C) Kaplan- Meier for the SEER 
cohort using mAJCC v.7 is shown; univariate Cox regression HRs are shown for the stage variable (separately for analysis with stage I and 
group C as reference categories). Abbreviations: excl, excluding; incl, including; mts, metastases; Tis: tumour in situ (1 case only).
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In addition, it would optimize terminology given that 
clinicians have been referring to this scenario as liver 
metastases for decades, which, in contrast with the 
strict definition based on AJCC v.7 and v.8 (M0), 
implies M1 disease. That said, it is tempting to spec-
ulate that stage may have been reported incorrectly in 
previous clinical trials. As an example, a post hoc anal-
ysis of ABC01/02/03 clinical trials exploring the role 
of palliative chemotherapy in biliary tract malignan-
cies was recently published.(16) In this study, 21.1% 
of patients diagnosed with iCCA were classified as 
“locally advanced” (defined as nonresectable disease 
FIg. 3. OS for each stage groups: ENS- CCA and SEER joined data. Using the proposed updated staging system, mAJCCv.8, provided 
a slightly higher Harrell’s C index (mAJCC v.8 (FIG. 3B); C index, 0.624) compared to the AJCC v.7 (FIG. 3A); C index, 0.614). In 
addition, the mAJCC v.8 allowed for a more clinically relevant separation of survival curves (while there was significant overlapping 
in AJCC v.7). (A) Kaplan- Meier for the ENS- CCA and SEER joined cohort using the proposed AJCC v.7 is shown; univariate Cox 
regression HRs are shown for the stage variable (with stage I as the reference category). (B) Kaplan- Meier for the ENS- CCA and SEER 
joined cohort using the proposed updated mAJCC v.8 is shown; univariate Cox regression HRs are shown for the stage variable (separately 
for analysis with stage I and stage IVa [liver metastases] as reference categories). Of the 820, 755, and 1,614 patients with stage III, IVa, 
and IVb disease, 418 (50.1%), 194 (25.7%), and 671 (41.6%), respectively, were N1. Abbreviations: excl, excluding; incl, including; mts, 
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in the absence of extrahepatic metastases), whereas no 
evidence of extrahepatic disease was found in 47.7%. 
Therefore, it could be argued that in these studies, a 
relevant proportion of patients were misclassified as 
“metastastic” in the absence of extrahepatic distant 
metastases.
One of the challenges of the proposed mAJCC v.8 
is the fact that in some countries, surgery is still pur-
sued even with evidence of liver metastases if disease 
is confined to the same hepatic lobe. However, this is 
not a widely adopted practice, and benefit of surgery 
in this context is not proven(36); therefore, individual 
decisions based on discussion in multidisciplinary 
teams are required.
Our study has some limitations. First, data were 
collected retrospectively, with the intrinsic draw-
backs of every retrospective analysis. Multivariable 
survival analysis was performed, adjusted to available 
clinical variables; in view of missing data, other vari-
ables, such as presence of cirrhosis, baseline tumor 
markers, and bilirubin level, among others, which 
could have been of interest, were not been included. 
In addition, the SEER registry was lacking some of 
the clinical information required (i.e., ECOG- PS), 
thereby limiting the applicability of a multivariable 
analysis. There were clear differences between the 
ENS- CCA training cohort and the internal valida-
tion cohort, with a bias toward a higher percentage 
of patients with advanced and noncurable disease 
in the training cohort, attributable to the center of 
origin of this cohort (cancer center with expertise 
in medical oncology for management of advanced 
disease). In addition, follow- up of patients included 
in the SEER registry was shorter than in the ENS- 
CCA registry. Given that the AJCC v.8 classification 
removed the T2a/T2b subgroups, it was not possible 
to assess the prognostic implications of liver metas-
tases in the most recent series, therefore relying on 
series related to the use of AJCC v.7. Given that 
both adjuvant and targeted therapies were rarely 
used therapeutic strategies during the years when 
the AJCC v.7 staging system was used, we did not 
have sufficient observations to explore the prognos-
tic impact of our staging system in patients treated 
with these treatment strategies. Thus, outcome 
was evaluated without accounting for the potential 
impact of the latest advances in treatments, includ-
ing both adjuvant and targeted therapies,(8,20) which 
could have produced (specially adjuvant therapies) 
an even more marked prognostic difference between 
M1a (liver metastases) and early- stage patients.
Even though the TNM stage provides a clinically 
meaningful classification for healthcare profession-
als, and adequately correlates with prognosis,(37) the 
staging of iCCA gained significant attention given 
that it was the latest to be incorporated.(38) In this 
regard, AJCC v.8 changes have been greatly wel-
comed, even though further observations have been 
sadly lacking.(30) In fact, in addition to our proposed 
mAJCC v.8 classification, other studies have shown 
that T2 and T3 iCCA tumors seem to have similar 
outcomes.(37,39) Finally, identification of other factors 
affecting prognosis, such as ECOG- PS (as shown this 
study), are also to be taken into account and adjusted 
for in future studies.
In conclusion, our study shows that patients diag-
nosed with iCCA and liver metastases have a worse 
prognosis compared to other early stages of disease 
and a better outcome compared to patients with extra-
hepatic metastases. On this basis, we propose that 
the latest AJCC v.8 needs to be revised by reclassi-
fying the condition of “liver metastases: multiple liver 
lesions, with or without vascular invasion” from T2 
into M1a disease, as part of a modified mAJCC v.8 
(reserving M1b for distant metastases). These changes 
are urgently needed to allow capturing of data regard-
ing presence of liver metastases, recently removed for 
the AJCC staging system for iCCA, in future stud-
ies thereby stratifying patients with liver metastases 
appropriately to evaluate the efficacy of these treat-
ments in clinical trials.
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